fda bans glp 1 compounding Compounded Semaglutide & Tirzepatide 2025: Safe Use Guide Novo pressures GLP-1 compounders as

Per the FDAs April 2026 clarification, a single 503A pharmacy can fill no more than four prescriptions per patient per calendar month, and compounded semaglutide cannot currently be produced by 503B outsourcing facilities because the drug is not on the 503B bulks list. The honest takeaway

We need prospective studies to define optimal dosing, duration, long-term safety, predictors of response and tolerability, and whether GLP-1 therapy can improve IBD-related outcomes beyond weight loss, Gold said

If postpartum weight management is a priority, discuss the timing with your provider

Case report: Wernicke-Korsakoff syndrome after bariatric surgery